Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ASH 2022
At #ASH25, @tamaciro shared updated results from the Phase II RESTORE trial evaluating elritercept in combination with ruxolitinib in patients with #myelofibrosis and anemia.
Find out more by clicking here:
👉 👈
#MPNsm #TrialUpdate #CTSM #HemOnc
Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE...
ow.ly
It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸
Click here to watch: 👉
#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...
ow.ly
In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.
Watch it here: 👉
#MMSM #Myeloma
Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis
Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...
ow.ly
🚨On December 23, 2025, the FDA approved mitapivat for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, based on data from the ENERGIZE & ENERGIZE-T trials.
Find out more about the approval here:
🗞️ 👉 https://ow.ly/gohh50XRPCq
Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸
Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:
👉 👈
#CLLsm #Leusm #CTSM
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...
ow.ly
ASH 2022
At #ASH25, @tamaciro shared updated results from the Phase II RESTORE trial evaluating elritercept in combination with ruxolitinib in patients with #myelofibrosis and anemia.
Find out more by clicking here:
👉 👈
#MPNsm #TrialUpdate #CTSM #HemOnc
Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE...
ow.ly
It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸
Click here to watch: 👉
#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...
ow.ly
In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.
Watch it here: 👉
#MMSM #Myeloma
Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis
Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...
ow.ly
🚨On December 23, 2025, the FDA approved mitapivat for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, based on data from the ENERGIZE & ENERGIZE-T trials.
Find out more about the approval here:
🗞️ 👉 https://ow.ly/gohh50XRPCq
Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸
Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:
👉 👈
#CLLsm #Leusm #CTSM
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...
ow.ly
